Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.

Saved in:
Bibliographic Details
Title: Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
Authors: Chen MF; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York., Lee JJ; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Choudhury NJ; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., Hui AB; Department of Radiation Oncology, Stanford University, Stanford, California., Jeng MY; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Zheng J; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Aly RG; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Sielski N; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York., Ahn L; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Pupo A; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Nesselbush MC; Department of Radiation Oncology, Stanford University, Stanford, California; Department of Biology, Stanford University, Stanford, California., Jabara I; Department of Radiation Oncology, Stanford University, Stanford, California; Department of Biology, Stanford University, Stanford, California., Wilcox JA; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York., Santomasso BD; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York., Lin AL; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York., Schaff L; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York., Chaft JE; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York., Riely GJ; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York., Kris MG; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York., Arfe A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Yang SR; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Young RJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York., Diehn M; Department of Radiation Oncology, Stanford University, Stanford, California; Department of Biology, Stanford University, Stanford, California; Stanford Cancer Institute, Stanford University, Stanford, California., Boire A; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology & Pathogenesis, Memorial Sloan Kettering Cancer Center, New York, New York., Yu HA; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address: yuh@mskcc.org.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2026 Mar; Vol. 21 (3), pp. 103505. Date of Electronic Publication: 2025 Oct 23.
Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1556-1380
DOI:10.1016/j.jtho.2025.10.012